Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;14(2):90-2.
doi: 10.4103/1319-3767.39627.

Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma

Abdullah Al-Kalbani  1 , Yasser Kamel
Affiliations

Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma

Abdullah Al-Kalbani et al. Saudi J Gastroenterol. 2008 Apr.

Abstract

A small percentage of patients with hepatocellular carcinoma (HCC) are candidates for curative treatment in form of resection or transplantation. There are different treatment options for unresectable HCC-like local ablative therapies and recently systemic therapy with Sorafenib. All of these have variable response rate and had been proven to improve survival. In the last few years, there is a growing interest in TheraSphere radioembolization. It consists of yttrium90 (Y-90) embedded into nonbiodegradable glass microspheres. It is selectively administered by intraarterial hepatic injection giving high doses of radiation to the tumor and sparing the liver parenchyma. It has been shown to improve survival and used as a bridge to transplantation and to downstage tumors for resection. Therasphere seems to have favorable safety profile and has been used in patients with portal vein thrombosis with successful outcome.

Keywords: Hepatocellular carcinoma; Y-90 microspheres; radioembolization.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Feldman . Sleisenger and Fordtran's Gastrointestinal and LiverDisease. 8th ed. Chapter 19.
    1. Salem R, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. Int J Radiat Oncol Biol Phys. 2006;66:S83–8. - PubMed
    1. Llovet J, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). Proceedings from the American Society of Clinical Oncology Conference; 2007; Chicago, IL.
    1. Goin JE, Salem R, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205–13. - PubMed
    1. Salem R, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response and survival. J Vasc Interv Radiol. 2005;16:1627–39. - PubMed